Collectively, our findings evidence that RBM47 affects PC development by regulating PDIA6-medaited PC cell proliferation and immune escape from cytotoxic NK cells and altering cellular metabolites, providing the novel therapeutic target for PC treatment. Here, PDIA6 is linked to pachyonychia congenita.